304 related articles for article (PubMed ID: 21940664)
21. ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
Xu B; Feng Y; Lv B; Xu G; Zhang L; Du J; Peng K; Xu M; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Seed B; Chen Y
Bioorg Med Chem; 2010 Jun; 18(12):4422-32. PubMed ID: 20576578
[TBL] [Abstract][Full Text] [Related]
22. High-yield functional expression of human sodium/d-glucose cotransporter1 in Pichia pastoris and characterization of ligand-induced conformational changes as studied by tryptophan fluorescence.
Tyagi NK; Goyal P; Kumar A; Pandey D; Siess W; Kinne RK
Biochemistry; 2005 Nov; 44(47):15514-24. PubMed ID: 16300400
[TBL] [Abstract][Full Text] [Related]
23. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats.
Han S; Hagan DL; Taylor JR; Xin L; Meng W; Biller SA; Wetterau JR; Washburn WN; Whaley JM
Diabetes; 2008 Jun; 57(6):1723-9. PubMed ID: 18356408
[TBL] [Abstract][Full Text] [Related]
24. A high-capacity membrane potential FRET-based assay for the sodium-coupled glucose co-transporter SGLT1.
Weinglass AB; Swensen AM; Liu J; Schmalhofer W; Thomas A; Williams B; Ross L; Hashizume K; Kohler M; Kaczorowski GJ; Garcia ML
Assay Drug Dev Technol; 2008 Apr; 6(2):255-62. PubMed ID: 18471079
[TBL] [Abstract][Full Text] [Related]
25. Development of a cell-based nonradioactive glucose uptake assay system for SGLT1 and SGLT2.
Kanwal A; Singh SP; Grover P; Banerjee SK
Anal Biochem; 2012 Oct; 429(1):70-5. PubMed ID: 22796500
[TBL] [Abstract][Full Text] [Related]
26. Identification of phlorizin binding domains in sodium-glucose cotransporter family: SGLT1 as a unique model system.
Raja M; Kinne RK
Biochimie; 2015 Aug; 115():187-93. PubMed ID: 26086341
[TBL] [Abstract][Full Text] [Related]
27. O-Spiro C-aryl glucosides as novel sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
Xu B; Lv B; Feng Y; Xu G; Du J; Welihinda A; Sheng Z; Seed B; Chen Y
Bioorg Med Chem Lett; 2009 Oct; 19(19):5632-5. PubMed ID: 19700318
[TBL] [Abstract][Full Text] [Related]
28. Bridging the gap between structure and kinetics of human SGLT1.
Sala-Rabanal M; Hirayama BA; Loo DD; Chaptal V; Abramson J; Wright EM
Am J Physiol Cell Physiol; 2012 May; 302(9):C1293-305. PubMed ID: 22159082
[TBL] [Abstract][Full Text] [Related]
29. Dapagliflozin Binds Specifically to Sodium-Glucose Cotransporter 2 in the Proximal Renal Tubule.
Ghezzi C; Yu AS; Hirayama BA; Kepe V; Liu J; Scafoglio C; Powell DR; Huang SC; Satyamurthy N; Barrio JR; Wright EM
J Am Soc Nephrol; 2017 Mar; 28(3):802-810. PubMed ID: 27620988
[TBL] [Abstract][Full Text] [Related]
30. Structural basis of inhibition of the human SGLT2-MAP17 glucose transporter.
Niu Y; Liu R; Guan C; Zhang Y; Chen Z; Hoerer S; Nar H; Chen L
Nature; 2022 Jan; 601(7892):280-284. PubMed ID: 34880493
[TBL] [Abstract][Full Text] [Related]
31. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
Meng W; Ellsworth BA; Nirschl AA; McCann PJ; Patel M; Girotra RN; Wu G; Sher PM; Morrison EP; Biller SA; Zahler R; Deshpande PP; Pullockaran A; Hagan DL; Morgan N; Taylor JR; Obermeier MT; Humphreys WG; Khanna A; Discenza L; Robertson JG; Wang A; Han S; Wetterau JR; Janovitz EB; Flint OP; Whaley JM; Washburn WN
J Med Chem; 2008 Mar; 51(5):1145-9. PubMed ID: 18260618
[TBL] [Abstract][Full Text] [Related]
32. Design of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: A History Driven by Biology to Chemistry.
Cai W; Jiang L; Xie Y; Liu Y; Liu W; Zhao G
Med Chem; 2015; 11(4):317-28. PubMed ID: 25557661
[TBL] [Abstract][Full Text] [Related]
33. Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+/H+ exchanger isoform 3 activity in the renal proximal tubule.
Pessoa TD; Campos LC; Carraro-Lacroix L; Girardi AC; Malnic G
J Am Soc Nephrol; 2014 Sep; 25(9):2028-39. PubMed ID: 24652792
[TBL] [Abstract][Full Text] [Related]
34. A selectivity study of sodium-dependent glucose cotransporter 2/sodium-dependent glucose cotransporter 1 inhibitors by molecular modeling.
Xu J; Yuan H; Ran T; Zhang Y; Liu H; Lu S; Xiong X; Xu A; Jiang Y; Lu T; Chen Y
J Mol Recognit; 2015 Aug; 28(8):467-79. PubMed ID: 25753971
[TBL] [Abstract][Full Text] [Related]
35. Natural Products as Lead Compounds for Sodium Glucose Cotransporter (SGLT) Inhibitors.
Blaschek W
Planta Med; 2017 Aug; 83(12-13):985-993. PubMed ID: 28395363
[TBL] [Abstract][Full Text] [Related]
36. Development of SGLT1 and SGLT2 inhibitors.
Rieg T; Vallon V
Diabetologia; 2018 Oct; 61(10):2079-2086. PubMed ID: 30132033
[TBL] [Abstract][Full Text] [Related]
37. C-aryl glucosides substituted at the 4'-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
Xu B; Feng Y; Cheng H; Song Y; Lv B; Wu Y; Wang C; Li S; Xu M; Du J; Peng K; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Roberge JY; Seed B; Chen Y
Bioorg Med Chem Lett; 2011 Aug; 21(15):4465-70. PubMed ID: 21737266
[TBL] [Abstract][Full Text] [Related]
38. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts.
Lee TM; Chang NC; Lin SZ
Free Radic Biol Med; 2017 Mar; 104():298-310. PubMed ID: 28132924
[TBL] [Abstract][Full Text] [Related]
39. Common mechanisms of inhibition for the Na+/glucose (hSGLT1) and Na+/Cl-/GABA (hGAT1) cotransporters.
Hirayama BA; Díez-Sampedro A; Wright EM
Br J Pharmacol; 2001 Oct; 134(3):484-95. PubMed ID: 11588102
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis and biological evaluation of (2S,3R,4R,5S,6R)-5-fluoro-6-(hydroxymethyl)-2-aryltetrahydro-2H-pyran-3,4-diols as potent and orally active SGLT dual inhibitors.
Xu G; Gaul MD; Kuo GH; Du F; Xu JZ; Wallace N; Hinke S; Kirchner T; Silva J; Huebert ND; Lee S; Murray W; Liang Y; Demarest K
Bioorg Med Chem Lett; 2018 Nov; 28(21):3446-3453. PubMed ID: 30268701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
